PTGER4 and non-small cell lung carcinoma: Cancer clinical trials to evaluate EP4 inhibitors are recruiting in trials of Grapiprant (ARY-007) in combination with pembrolizumab in subjects with either advanced MSS colorectal cancers (NCT03658772) or, in a separate trial in advanced NSCLC (NCT03696212) (Mizuno et al., 2019; Take et al., 2020).